Pfizer wins EU approval for MabThera biosimilar
The drug will be available to treat certain cancers and autoimmune conditions
Read More
Tag: Ruxience
Pfizer’s Rituxan biosimilar bags FDA approval
The treatment has been approved in adult patients with non-Hodgkin’s lymphoma.
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
